The Society of Urologic Oncology (SUO) convenes its 20th Annual Scientific Meeting in Washington, DC, from December 4 to 6 at the Renaissance Washington DC Downtown Hotel.
In addition to state-of-the-art talks on prostate, kidney, and bladder cancer and discussions about strategies in urologic oncology, the conference will feature more than 250 poster displays and oral presentations that report study findings from investigators worldwide, according to the SUO web site (www.suonet.org).
Further, on December 4, the SUO, in conjunction with the SUO Clinical Trials Consortium (SUO-CTC), is sponsoring a half-day educational symposium on clinical research and clinical trials. “This program seeks to ensure that each fellow has the tools required to quickly engage in clinical trials upon graduation and to facilitate engagement in the SUO-CTC,” the society’s web site noted.
Continue Reading
On December 4, prior to the annual meeting, there will be a general session titled “SUO Symposium on Clinical Research and Clinical Trials.” Among the topics to be discussed in this session are the roles and responsibilities of the investigator (Robert G. Uzzo, MD), regulatory issues and institutional review boards (Sia Daneshmand, MD) and grants and funding for clinical trials (Daniel W. Lin, MD). The session runs from 7:00 am to 12:00 pm.
The annual meeting, which begins at 1 pm on December 4, features general sessions on are variety of timely clinical topics. For example, a session titled “Organ Preservation in Urologic Oncology,” scheduled for December 4 from 1:00 pm to 2:30 pm, will include presentations on muscle-invasive bladder cancer (Robert Huddart, MBBS), kidney cancer (Steven Charles Campbell, MD, PhD), penile cancer (Philippe E. Spiess, MD, MSc), and prostate cancer (Scott E. Eggener, MD). Kidney cancer is the focus of a general session on December 5 from 8:00 am to 9:10 am. Topics include optimizing imaging surveillance after treatment for localized renal cell carcinoma (RCC) (Suzanne B. Merrill, MD), the future of predictive biomarkers in RCC (Joshua M. Lang, MD, MS), building a surgical team to improve outcomes for complex renal surgery/IVC thrombectomy (Viraj A. Master, MD, PhD), and stereotactic radiation for treatment of RCC (Vitaly Margulis, MD).
